Experimental drug offers first real hope for pancreatic cancer patients

Pancreatic cancer has long been one of the deadliest diagnoses. Few treatments exist, and those available do little to help patients. For decades, experimental drugs failed in trials. Many researchers thought the disease's biological obstacles were simply impossible to overcome.

That view has shifted dramatically. A drug called daraxonrasib, moving toward regulatory approval, is the first to meaningfully extend survival for pancreatic cancer patients. The drug works by targeting a cellular protein that fuels nearly all pancreatic tumors and many lung and colon cancers. These three cancer types are the leading causes of cancer deaths worldwide.

Some scientists now believe this approach could be the most significant advance in cancer treatment in 15 years, since immunotherapy arrived. The breakthrough follows decades of research funded by both government and private sources, with many false starts and failed attempts along the way. Researchers had to overturn ideas that the scientific community had accepted as fact.

The target was a smooth protein inside cells called KRAS, which becomes altered in certain cancers and drives their growth. Scientists often described it as a "greasy ball," seemingly impossible to attack. "Every time there was an advance, it led to another dumping of dogma and finding out that what everybody assumed was true was actually not true," said Adrienne Cox, a researcher at the University of North Carolina.

The long path to daraxonrasib shows how persistence in science can eventually break through barriers that once seemed unbeatable. The drug's success in trials suggests the same approach may work against other cancer types as well.